NASDAQ:ALGS

Aligos Therapeutics Q1 2026 Earnings Results & Report

Aligos Therapeutics logo
$1.66 -0.44 (-20.95%)
Closing price 04:00 PM Eastern
Extended Trading
$1.68 +0.03 (+1.51%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aligos Therapeutics beat analyst expectations on both earnings and revenue in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$2.21 versus the -$2.29 consensus estimate, while revenue of $2.83 million topped the $250 thousand estimate by $2.58 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Aligos Therapeutics EPS Results

Actual EPS
-$2.21
Consensus EPS
-$2.29
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Aligos Therapeutics Revenue Results

Actual Revenue
$2.83 million
Expected Revenue
$250 thousand
Beat/Miss
Beat by +$2.58 million
YoY Revenue Growth
N/A

Aligos Therapeutics Q1 2026 Earnings FAQ

Aligos Therapeutics (NASDAQ:ALGS) reported earnings of -$2.21 per share for Q1 2026, beating the consensus estimate of -$2.29. The report was announced on Thursday, May 7, 2026.

Aligos Therapeutics reported revenue of $2.83 million for Q1 2026, against a consensus estimate of $250 thousand.

Aligos Therapeutics Earnings Headlines

Aligos Therapeutics (NASDAQ:ALGS) Rating Lowered to Sell at Wall Street Zen
Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
See More Aligos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email.

About Aligos Therapeutics

Aligos Therapeutics (NASDAQ:ALGS) is a clinical-stage biopharmaceutical company based in South San Francisco, California. Founded in 2018, it focuses on developing medicines for viral infections and liver diseases.

The company’s research has included investigational treatments for chronic hepatitis B and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Its development work has involved small-molecule drug candidates, including approaches intended to interfere with viral replication.

Aligos is focused on research and clinical development rather than marketing approved medicines. Its programs are investigational, and their development status may change as clinical testing and company priorities evolve.

View Aligos Therapeutics Profile